drugset / Trial / NCT00796692

Nadroparin for the Initial Treatment of Pulmonary Thromboembolism

NCT00796692

Phase 4 Completed 274 enrolled Beijing Chao Yang Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Low-molecular-weight heparin (LWMH) appears to be at least as effective and safe as standard, unfractionated heparin (UFH)for the treatment of patients with deep vein thrombosis(DVT) and may also be so in patients with pulmonary thromboembolism (PTE). Only limited data are available on the evaluation of body weight adjusted LWMH and standard UFH for the initial treatment of PTE in Chinese population. The aim of this study is to determine whether body weight-adjusted, subcutaneous Nadroparin is as effective and safe as UFH for treatment of patients with objectively documented PTE.

Timeline

Start
2002-06
Primary completion
2006-02
Completion
2006-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Heparin Other / unclassified 18 iu/kg Intravenous
Subject Nadroparin Calcium Other / unclassified 86 iu/kg Subcutaneous